Boehringer Ingelheim at IPVS 2026: Promoting Swine Health Through Science, Prevention and Collaboration

At IPVS 2026 in Ho Chi Minh City, leading experts in pig health gathered to discuss the challenges shaping the industry today: from the complexity of managing disease in modern production systems to the latest evidence on PCV2 vaccination strategies, the synergistic impact of co-infections, and the practical realities of multi-antigen vaccination platforms — all framed within Boehringer Ingelheim Animal Health's vision of prevention, collaboration, and integrated herd health management.

Gerard Ensink:  

At IPVS 2026, Gerard Ensink, Head of Global Strategic Marketing Swine at Boehringer Ingelheim Animal Health, answers a key question: what makes Boehringer Ingelheim's approach to swine health different? From a vaccine-only prevention philosophy to a collaborative model with academia, practitioners, and industry partners, Ensink explains how Boehringer Ingelheim is addressing the growing complexity of swine health management. 

Oliver Duran 

Why is it so difficult to manage disease in pig production systems nowadays? Oliver Gómez Durán addresses this question at IPVS 2026 and breaks down the dynamic, multifactorial nature of swine health — from pathogen interactions to the complexity of multi-site production, biosecurity, and diagnostics — making the case for a systematic, integrated approach to disease control. 

Joaquím Segalés (1) 

At IPVS 2026, Dr. Quim Segalés from IRTA-CReSA addresses why a whole-herd vaccination strategy is essential for effective PCV2 control, compared to traditional pig-level approaches?. He discusses the limitations of individual-based protocols and the rationale behind extending vaccination coverage to the entire herd — a key consideration for veterinarians designing PCV2 control programmes. 

Joaquím Segalés (2) 

PCV2d is increasingly detected in the field, but most vaccines are still based on PCV2a. At IPVS 2026, Dr. Quim Segalés from IRTA-CReSA examines whether current PCV2a-based vaccines still provide adequate cross-protection against the circulating genotype. He reviews the evidence behind cross-genotype protection and what it means for surveillance and vaccination strategies going forward. 

Marcelo Almeida (1) 

When PRRS meets PCV2 or Mycoplasma hyopneumoniae, 1+1 is no longer 2. At IPVS 2026, Dr. Marcelo Almeida from Iowa State University examines the role and impact of PRRS in herds with concurrent PCV2 and Mhyo infection — and explains why the synergistic effect of these co-infections makes disease far more severe, calling for vaccination protocols and management conditions that address all three pathogens together. 

Marcelo Almeida (2) 

Between PRRS and PCV2, which one is more devastating when left uncontrolled? Dr. Marcelo Almeida from Iowa State University confronts one of the most debated questions in swine medicine at IPVS 2026 — with direct implications for how producers and veterinarians should prioritise disease control.

Joseph Yaros 

At IPVS 2026, Joseph Yaros, President of Pipestone Management China Division, draws on over a decade of field experience with the 3-Flex vaccination platform to answer a practical question: is combining 3 antigens in a single post-weaning intervention too stressful for piglets, and does it affect their immune response and performance? 

By bringing together world-leading experts and the latest scientific evidence, Boehringer Ingelheim Animal Health reaffirmed its commitment to advancing swine health through innovation, collaboration, and integrated prevention strategies, supporting veterinarians and producers in tackling today's and tomorrow's challenges.